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Randomised trialAbstract Purpose: NovoTTF-100A is a portable device delivering low-intensity, intermedi-
ate frequency electric ﬁelds via non-invasive, transducer arrays. Tumour Treatment Fields
(TTF), a completely new therapeutic modality in cancer treatment, physically interfere with
cell division.
Methods: Phase III trial of chemotherapy-free treatment of NovoTTF (20–24 h/day) versus
active chemotherapy in the treatment of patients with recurrent glioblastoma. Primary end-
point was improvement of overall survival.
Results: Patients (median age 54 years (range 23–80), Karnofsky performance status 80%
(range 50–100) were randomised to TTF alone (n = 120) or active chemotherapy control
(n = 117). Number of prior treatments was two (range 1–6). Median survival was 6.6 versus
6.0 months (hazard ratio 0.86 [95% CI 0.66–1.12]; p = 0.27), 1-year survival rate was 20%
and 20%, progression-free survival rate at 6 months was 21.4% and 15.1% (p = 0.13), respec-
tively in TTF and active control patients. Responses were more common in the TTF arm (14%
versus 9.6%, p = 0.19). The TTF-related adverse events were mild (14%) to moderate (2%)
skin rash beneath the transducer arrays. Severe adverse events occurred in 6% and 16%
(p = 0.022) of patients treated with TTF and chemotherapy, respectively. Quality of life anal-
yses favoured TTF therapy in most domains.
Conclusions: This is the ﬁrst controlled trial evaluating an entirely novel cancer treatment
modality delivering electric ﬁelds rather than chemotherapy. No improvement in overall sur-
vival was demonstrated, however efﬁcacy and activity with this chemotherapy-free treatment
device appears comparable to chemotherapy regimens that are commonly used for recurrent
glioblastoma. Toxicity and quality of life clearly favoured TTF.
 2012 Elsevier Ltd.Open access under CC BY-NC-ND license. 1. Background
Glioblastoma is the most prevalent primary malig-
nant brain tumour in adults. Median survival with opti-
mal therapy is only 15 months from diagnosis, and most
tumours recur within 9 months of initial treatment.1 At
the time of disease recurrence, treatment options for
glioblastoma patients are limited. Repeat surgery may
be considered in approximately 20% of patients,2–4 and
re-irradiation is possible in rare circumstances. For most
patients chemotherapy is indicated at disease recurrence,
with the choice of drug varying greatly. In the United
States, bevacizumab has been provisionally approved
for recurrent glioblastoma, while the European Medi-
cines Agency (EMEA) rejected the application in the
absence of a controlled trial.5,6 Cytotoxic agents most
frequently used are alkylating agents like nitrosoureas
(e.g. lomustine [CCNU] or carmustine [BCNU],7 pro-
carbazine8 or re-treatment with temozolomide.9,10
Response rates are below 10%, progression-free survival
rates at 6 months <20%.7,8 In the absence of an estab-
lished and satisfactory standard treatment, bevacizumabalone and in combination with irinotecan and experi-
mental treatments are commonly used.11–13
Overall survival (OS) from recurrence is commonly
short and without eﬀective therapy rarely exceeds 3–
5 months.14–19 In a randomised trial of repeat surgery
with implantation of carmustine wafers versus placebo
median survival was 6.5 versus 4.7 months.20 With
active therapy, a median survival of 7 months (range
5–9.2 months)7–10,12,13,21–24 has been reported. A recent
randomised comparison of enzastaurin versus lomustine
at ﬁrst recurrence demonstrated a median survival of
7.1 months, with 19% of patients alive and progres-
sion-free at 6 months when treated with lomustine.7
Based on these results active chemotherapy as salvage
treatment for patients with recurrent glioma is recom-
mended, which strives to improve survival and quality
of life despite inherent chemotherapy-related toxicity.
The NovoTTF-100A system (Novocure Ltd., Haifa,
Israel) is a portable device delivering low intensity, inter-
mediate frequency, alternating electric ﬁelds (Tumour
Treating Fields; TTF) using non-invasive, disposable
transducer arrays (Fig. 1A). These ﬁelds physically
Fig. 1. Female patient wearing the portable NovoTTF-100A device (A). Grade 2 skin rash underneath transducer arrays in a diﬀerent patient (B).
With the patients’ permission.
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microtubule subunits in the mitotic spindle during the
metaphase to anaphase transition25 and by dielectroph-
oretic movement of intracellular macromolecules and
organelles during telophase.26,27 This causes failure of
cytokinetic furrow formation and resultant mitotic bleb-
bing, leading to the disruption of chromosome segrega-
tion and eventual cell death. The exact pathways by
which spindle disruption and physical aggregation of
macromolecules lead to cell death are unknown. TTF
has been tested in several pilot clinical studies26,28,29
including a small single arm study as monotherapy for
recurrent glioblastoma. The results of this pilot trial
were promising26 and served as the basis of this phase
III trial comparing NovoTTF-100A monotherapy
(TTF) to best active chemotherapy according to the
physician’s best choice (active treatment control group).
This report describes for the ﬁrst time the eﬃcacy and
safety of this entirely novel treatment modality com-
pared to widely accepted active chemotherapies for the
treatment of recurrent glioblastoma patients.2. Methods
2.1. Patient selection
Patients 18 years or older with histologically con-
ﬁrmed glioblastoma (World Health Organization grade
IV astrocytoma) were eligible following radiologically
conﬁrmed disease progression (Macdonald criteria).
Patients had a Karnofsky performance status P70%
and adequate haematologic, renal and hepatic function
(absolute neutrophil count P1000/mm3; haemoglobin
P100 g/L platelet count, P100,000/mm3; serum creati-
nine level 61.7 mg/dL (<150 lmol/L); total serum bili-
rubin level 6 the upper limit of normal and liver-
function values, <3 times the upper limit of normal).
Prior therapy must have included radiotherapy (with
and without concomitant and/or adjuvant temozolo-
mide). There was no limit on number or type of priortherapies or recurrences. Patients with infra-tentorial
tumour location were excluded, as were patients with
implanted electronic medical devices (e.g. pacemaker,
programmable ventriculo-peritoneal shunt). All patients
provided written informed consent, and the study was
approved by the institutional review boards or ethics
committees of all participating centres.2.2. Study design and treatment
Patients were randomised at a 1:1 ratio to receive
either TTF monotherapy (without chemotherapy) or
the best available active chemotherapy according to
the local physician’s choice (active control). Randomisa-
tion was performed using random block sizes and was
stratiﬁed by centre and according to whether patients
underwent surgery for their latest recurrence prior to
trial entry. Assigned treatment had to start within
1 week of randomisation, and was to be continued until
disease progression or intolerance.
For patients assigned to the TTF group four trans-
ducer arrays were placed on the patient’s shaved scalp
and connected to a portable, battery or power supply
operated device (NovoTTF-100A) which was set to gen-
erate 200 kHz electric ﬁelds within the brain in two per-
pendicular directions (operated sequentially). Field
intensity was set at >0.7 V/cm at the centre of the brain.
Patients were trained on how to operate the device and
then continued treatment at home. Treatment was con-
tinuous while maintaining normal daily activity. Trans-
ducer arrays were replaced by the patients, their
caregivers or device technicians once or twice a week.
Prior to placement, the scalp was shaved carefully with
an electric razor in order to avoid skin wounding, trans-
ducer arrays were supplied sterile. Although uninter-
rupted treatment was recommended, patients were
allowed to take treatment breaks of up to an hour, twice
per day, for personal needs (e.g. shower). In addition,
they were allowed to take 2–3 days oﬀ treatment at the
end of each 4 weeks of treatment (which is the minimal
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tumour growth).30
Patients assigned to the active control received chemo-
therapy at the local investigators discretion. The best ava-
ilable chemotherapy was prescribed according to local
practice and depending on prior treatment exposure.
2.3. Patient surveillance and follow up
Baseline examinations included a gadolinium-
enhanced magnetic resonance imaging (MRI) of the
brain, full blood counts, blood chemistry tests, blood
coagulation tests, electrocardiogram (ECG), physical
examination including a detailed neurological examina-
tion and quality of life (QoL) questionnaire (European
Organisation for Research and Treatment of Cancer
(EORTC) QLQ C-30).
Patients were followed once a month, including labo-
ratory tests. MRI was repeated every 2 months. QoL
questionnaires were completed at baseline and then
every 3 months. Tumour response and progression were
determined by blinded central radiology review, accord-
ing to Macdonald criteria.31 When an MRI could not be
obtained, progression was assessed clinically based on
neurological status, steroid dosing, adverse events and
investigator assessment of progression.
Adverse events were recorded prospectively accord-
ing to National Cancer Institute Common Toxicity Cri-
teria (NCI CTC V3.0)
2.4. Statistical analysis
The primary end-point was OS. Secondary end-
points were progression free survival (PFS), the percent-
age of patients alive and progression-free at 6 months
(PFS6), 1-year survival rate, radiological response rate
(RR), QoL and safety. OS and PFS were computed
from the day of randomisation until event or censored
at last follow-up according to the Kaplan–Meier
method, with 2-sided logrank statistics for comparison.
The study had an 80 per cent power at a signiﬁcance
level of 0.05 to detect a 60 per cent increase in median
OS (hazard ratio for death, 0.63). All analyses were per-
formed using the intent to treat population of all ran-
domised patients, patients lost to follow-up were
censored at the time of last contact. A Cox proportional
hazards model was used to adjust for confounding base-
line variables (continuous and categorical). The survival
data were tested for proportional hazards and the
assumption of proportionality met. The Cox model
was performed in two steps; ﬁrst, all protocol pre-spec-
iﬁed baseline variables were tested directly for interac-
tions with OS; then a reduced model was performed
testing the eﬀect of all variables with signiﬁcant interac-
tions (p < 0.05) with OS together on the treatment eﬀect
of TTF versus active chemotherapy. Secondary end-
points are presented without adjustment. QoL is pre-sented as change from baseline to 3 months for each
of the subscale domains and symptom scales of the
QLQ-C30 questionnaire.2.5. Organisational aspects
The trial was registered on www.clinicaltrials.gov,
NCT#00379470. The trial was funded and sponsored
by Novocure Ltd. Statistical analysis was performed
by David Steinberg. The manuscript was written by
Roger Stupp and Eilon Kirson, with substantial input
by all co-authors. The ﬁnal manuscript was reviewed
and approved by all authors. The statistician and the
corresponding author had unrestricted access to all data.2.6. Role of the funding source
Representatives of the study sponsor were involved in
the study design, data collection, data analysis, data
interpretation and writing of the report. Data analysis
was performed by David Steinberg, a compensated inde-
pendent biostatistician. The corresponding author had
full access to all data in the study and had ﬁnal respon-
sibility for the decision to submit for publication.3. Results
3.1. Patients
From September 2006 until May 2009, 237 patients
from 28 institutions in 7 countries were randomly
assigned to receive TTF monotherapy (120 patients) or
active control chemotherapy (117 patients). The baseline
patient characteristics were balanced (Table 1). The
median age was 54, and a quarter of the patients had
undergone some surgical resection of the recurrent
tumour prior to enrolment into the trial. More than
80% of patients had failed two or more prior lines of
chemotherapy (Psecond recurrence) and 20% of the
patients had failed bevacizumab prior to enrolment.
Histology was per local pathological diagnosis; in 8%
a history of a prior lower grade glioma had been
reported (secondary glioblastoma). Methyl-guanine
methyl-transferase (MGMT) gene promoter methyla-
tion, an important predictive factor for beneﬁt of tem-
ozolomide chemotherapy in newly diagnosed
glioblastoma, was not assessed in this trial of patients
with recurrent disease.3.2. Patient disposition, treatment and compliance
In the TTF group, 116 of 120 patients (97%) started
treatment and 93 patients (78%) completed 4 weeks of
therapy (1 cycle). Twenty-seven patients discontinued
treatment early, often within a few days, due to non-
compliance or inability to handle the device (trial ﬂow
2196 R. Stupp et al. / European Journal of Cancer 48 (2012) 2192–2202diagram). Four patients had pre-treatment events
related to the progressive nature of their disease and
never started therapy with the device. In the TTF
patients who started treatment (116 patients) mean com-
pliance was measured by downloading a log ﬁle from the
device, which recorded the actual time TTF therapy was
delivered. Median compliance was 86 per cent (range
41–98%) of the time in each treatment month, translat-
ing into a mean use of 20.6 h per day.Randomized (n=237) 
Allocated to TTF therapy (n=120) Allocated to active chemotherapy (n 117)    
¨ Received TTF therapy (n=116)
    =
¨ Received active chemotherapy (n=113)
¨ Did not receive TTF therapy (d/t withdrawal of 
consent) (n=4)
¨ Did not receive active chemotherapy (d/t pre-
treatment event) (n 4) 
- Completed at least 1 course (n=79)
  =
- Completed at least 1 course (n=112)
Lost to survival follow-up (n=4) Lost to survival follow-up (n=5)
Lost to safety follow-up (d/t withdrawal of Lost to safety follow-up (d/t withdrawal of 
consent) (n=4) consent) (n=26)
Analysed for survival (n=120) Analysed for survival (n=117)
Analysed for safety (n=116) Analyzed for safety (n=91)
trial flow diagramIn the active control group, 113 of 117 patients (97%)
started chemotherapy and all but 1 patient completed
one full treatment course of the chosen chemotherapy.
In four patients disease related adverse events and
tumour progression prevented the initiation of the
planned chemotherapy, they only received supportive
care (hospice care). Twenty-one patients randomised
to the control group decided not to return to the inves-
tigational site for treatment, thus details on disease pro-
gression and toxicity are not available. Most of patients
received single agent or a combination chemotherapy
regimen containing bevacizumab (31%), or irinotecan
(31%), followed by nitrosoureas (25%), carboplatin
(13%), temozolomide (11%) or various other agents
(5%; Supplementary Table 1).
3.3. Survival, progression and radiological response
At a median follow up of 39 months, 220 patients had
died (93%). Median survival was marginally higher in
the TTF group compared to active control chemother-apy (6.6 versus 6.0 months, respectively). One-year sur-
vival proportion was 20% in both groups, the 2- and
3-year survival rates survival rates were 8% (95% CI 4,
13) and 4% (95% CI 1, 8) versus 5% (95% CI 3, 10)
and 1% (95% CI 0, 3), for TTF versus active control,
respectively (Fig. 1A). The hazard ratio for death was
0.86 (95% CI 0.66, 1.12) in favour of NovoTTF
(p = 0.27). Adjusting for baseline characteristics using
a Cox proportional hazards model did not substantiallyalter the results. In the active chemotherapy control arm
of the trial, survival was not signiﬁcantly aﬀected by the
choice of chemotherapy (Cox proportional hazards test;
p = 0.66).
More objective radiological responses (partial and
complete responses) were seen in the TTF group than
in the active control chemotherapy group (14 versus 7,
respectively), translating into a response rate in evalu-
ated patients of 14.0% (95% CI 7.9–22.4%) versus
9.6% (95% CI 3.9–18.8%), respectively (chi squared
p = 0.19). All three complete responses were observed
in the TTF group. Two exemplary partial responses
from TTF are shown in Fig. 3.
The trial had been designed for superiority. Since the
control group in the trial is an active chemotherapy con-
trol which showed similar eﬃcacy to that seen in previ-
ous trials and the device was used as monotherapy it is
reasonable to analyse the results also in the context of
a non-inferiority analysis. The HR for death in the
TTF group compared to the active control chemother-
apy group was below 1.0 (0.86; 95% CI 0.66–1.12), indi-
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Fig. 2. Overall survival (A) and progression free survival (B) Kaplan–Meier curves.
Table 1
Baseline characteristics.
Tumour Treatment Fields (TTF) (n = 120) Active control (n = 117)
# pts (%) # pts (%)
Characteristics
Age, median (range) 54 years (24–80) 54 years (29–74)
Gender
Male 92 (77) 73 (62)
Female 28 (23) 44 (38)
Histology
Glioblastoma 100% 100%
Prior lower grade glioma 10 (8) 9 (8)
Karnofsky performance status, median (range) 80% (50–100) 80% (50–100)
Steroid use at enrolment
Yes 55 (46) 62 (53)
No 55 (46) 49 (42)
Unknown 10 (8) 6 (5)
Largest tumour diameter at randomisation, median (range) 6.1 cm (0–15.2) 5.5 cm (0–16.2)
Interval from initial glioma diagnosis, median (range) 11.8 months (3.2–99.3) 11.4 months (2.9–77.1)
Prior therapy
1st recurrence 11 (9) 17 (15)
2nd recurrence 58 (48) 54 (46)
3rd or greater recurrence 51 (43) 46 (39)
Surgery
Debulking before enrolment 33 (28) 29 (25)
Debulking at any stage 95 (79) 99 (85)
Biopsy only 25 (21) 18 (15)
Radiotherapy 100% 100%
With concomitant temozolomide 103 (86) 96 (82)
No concomitant temozolomide 15 (13) 20 (17)
Unknown 2 (1) 1 (1)
Prior adjuvant (maintenance) temozolomide 100 (83) 89 (76)
Median no of cycles 4 (0–19) 3 (0–27)
Prior bevacizumab 23 (19) 21 (18)
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chemotherapy.PFS showed a similar trend in favour of TTF patients
as seen for OS (Fig. 1B). Median PFS was 2.2 and
2198 R. Stupp et al. / European Journal of Cancer 48 (2012) 2192–22022.1 months for TTF and active control groups, respec-
tively (Fig. 2; HR 0.81, 95% CI 0.60–1.09; log rank
p = 0.16). PFS6 was 21.4 per cent (95% CI 13.5–29.3)
in the TTF group and 15.1 per cent (95% CI 7.8–22.3)
in the active control group (chi squared p = 0.13).3.4. Safety and toxicity
As expected from the mechanism of action of TTF
therapy and the fact that its delivery is localised to the
head, the typical systemic side-eﬀects of chemotherapies
were not observed in the TTF treated patients. Mild to
moderate (grade 1 and 2) contact dermatitis on the scalp
beneath the transducer arrays occurred in 16% of TTF
patients (Fig. 1B). This condition was easily treated with
topical corticosteroids, resolved completely after treat-
ment, was stopped and did not require substantial treat-
ment breaks.
Patients receiving active control chemotherapy expe-
rienced toxicity related to pharmacologic mechanism of
the agents used. A list of grade 2–4 adverse events by
organ system and adverse event terms seen in more than
2% of patients in either group is presented in Table 2. As
expected, there were signiﬁcantly more gastrointestinal,
haematological and infectious adverse events seen in
the chemotherapy group than in the TTF group. SevereFig. 3. Exemplary T1 weighted magnetic resonance imaging (MRI) image
with partial response to therapy. (A) A 48 years old male with prior grad
biopsy. The subject progressed 7 months after receiving chemoradiothera
12 months) and remained stable for an additional 36+ months on TTF. (B
third time after receiving chemoradiotherapy, adjuvant temozolomide (2
sorafenib (one cycle). The subject had a partial response to TTF therap
8 months while on TTF.(grades 3 and 4) toxicity was observed in only 3% of
patients.3.5. Quality of life
Longitudinal Quality of Life (QOL) could be ana-
lysed in the patients who remained on study therapy
for P3 months and for whom QoL data were available
(63 patients, 27%). In the domains of global health and
social functioning no meaningful diﬀerences between
chemotherapy and TTF were observed. However, cogni-
tive and emotional functioning favoured TTF. Physical
functioning may be slightly worse with TTF, while role
functioning favoured TTF (Fig. 4A). Symptom scale
analysis is in accordance to treatment-associated toxic-
ity; appetite loss, diarrhoea, constipation, nausea and
vomiting were directly related to the chemotherapy
administration. Increased pain and fatigue was reported
in the chemotherapy-treated patients and not in the TTF
treatment group (Fig. 4B).3.6. Treatment after progression
In order to rule out the eﬀect of subsequent treat-
ments on the OS results reported above, we compared
the number and type of post-progression treatments
patients received after failing the trial therapy. Due tos with gadolinium from two Tumour Treatment Fields (TTF) patients
e II astrocytoma which transformed to glioblastoma (based on tissue
py, and subsequently responded to TTF therapy (partial response at
) A 55 years old male with primary glioblastoma who recurred for the
cycles), bevacizumab with irinotecan (3 months) and erlotinib with
y after 4 months of treatment and remained stable for an additional
Table 2
Treatment-emergent adverse events Pgrade 2 by body system.
System Adverse event term Tumour Treatment Fields (TTF) (n = 116) Active control (n = 91)
% (% gr. 3 + 4) % (% gr. 3 + 4)
Haematological 3 (0) 17 (4)
Leucopenia 0 (0) 5 (1)
Neutropenia 0 (0) 2 (1)
Thrombocytopenia 1 (1)a 7 (2)
Gastrointestinal disorders 4 (1) 17 (3)
Abdominal pain 0 (0) 3 (0)
Diarrhoea 0 (0) 6 (2)
Nausea/vomiting 2 (0) 7 (0)
General deterioration and malaise 5 (1) 6 (1)
Infections 4 (0) 8 (1)
Skin rash (transducer arrays) 2 (0) 0 (0)
Metabolism and nutrition disorders 4 (1) 6 (3)
Musculoskeletal disorders 2 (0) 5 (0)
Nervous system disorders 30 (7) 28 (7)
Brain oedema 0 (0) 2 (0)
Cognitive disorder 2 (1) 2 (1)
Convulsion 7 (2) 5 (2)
Dysphasia 2 (0) 1 (0)
Headache 8 (1) 6 (0)
Hemianopsia 1 (0) 3 (1)
Hemiparesis 3 (1) 2 (1)
Neuropathy peripheral 2 (0) 2 (0)
Psychiatric disorders 5 (0) 4 (0)
Renal and urinary disorders 3 (1) 3 (0)
Respiratory disorders 1 (0) 3 (1)
Vascular disorders 3 (1) 4 (3)
Pulmonary embolism 1 (1) 2 (2)
Hypertension 1 (0) 1 (1)
Deep vein thrombosis 1 (0) 1 (0)
a Thrombocytopenia from prior chemotherapy, normalised subsequently.
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(most patients were at their second or subsequent recur-
rence), only 5.8% of the TTF-treated patients and 10.3%
of the chemotherapy-treated patients received subse-
quent salvage antitumour therapy (chi square p = 0.24)
(mainly bevacizumab, irinotecan, nitrosoureas and tem-
ozolomide). The majority of patients received only sup-
portive care once tumour progression developed.
4. Discussion
Tumour treatment with alternating electrical ﬁelds
that interfere with the metaphase to anaphase transition
in dividing tumour cells is an entirely novel cancer treat-
ment modality. We report the ﬁrst prospective, random-
ised, controlled study using this new treatment modality
in the most aggressive primary brain tumour. Although
glioblastoma diﬀusely inﬁltrates the brain, it almost
never metastasises and is thus amenable to a loco-regio-
nal therapy.
Prognosis of patients with recurrent glioblastoma is
poor, and chemotherapy is usually recommended.
Depending on prior treatments and treatment centre
expertise, variable chemotherapy agents alone or in
combination are commonly prescribed. Our randomised
trial compared this standard chemotherapy per localpractice (active treatment control group) with TTF in
a prospective, multicentre phase III trial. Although the
trial did not reach its primary end-point of improved
survival compared to active chemotherapy, this new
minimally invasive and chemotherapy-free local treat-
ment modality demonstrated a statistically non-signiﬁ-
cant increased response rate (14 versus 9.6%, p = 0.19),
an improved PFS6 rate (21% versus 15%, p = 0.13),
and a trend towards reduction of the risk of death (haz-
ard ratio 0.86, 95% CI 0.66–1.12, p = 0.27), as well as
sustained improvement in QoL.
These results cannot be explained by subsequent sal-
vage chemotherapy, as few patients received additional
therapy after failure of protocol treatment. Importantly,
the majority of our patients were recruited to the trial at
an advanced stage of the disease, after failure of two or
more chemotherapy agents, while other trials in recur-
rent glioblastoma usually only enrol patients at ﬁrst
recurrence. It is also notable that 20% of patients had
failed prior bevacizumab therapy, a population that
usually fares poorly with most subsequent treatments.
One limitation of the study was the absence of a pla-
cebo or treatment-free control arm. In the setting of
advanced disease and chemotherapy considered indi-
cated and eﬀective, such a control would hardly have
been acceptable to patients and physicians alike. Fur-
AB
Fig. 4. QLQ C30 longitudinal change from base to 3 months. (A) General functional scales (an increase in percentage corresponds to an increase in
QOL). (B) Symptom scales (an increase in percentage corresponds to a decrease in QOL).
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rior eﬃcacy versus investigational treatments in two
recent randomised trials. And based on high response
rates and prolonged survival compared to historical con-
trols bevacizumab has received accelerated Food and
Drug Administration (FDA) approval. Furthermore,
the observation of objective responses in 14 patients with
NovoTTF alone (median time since end of prior RT
7 months, thus unlikely to be all pseudoprogression)
strongly suggests singular activity of this device.
Another limitation is the somewhat heterogeneous
patient population, with patients included after progres-
sion of one or several lines of prior chemotherapy. This
underscores the demand from patients for further treat-
ments, even when the expected beneﬁt of a 2 months
prolongation in PFS may appear modest. In the ongoing
randomised phase III trial for newly diagnosed glioblas-
toma, only patients non-progressive after completion of
chemoradiation are eligible (Novocure EF-14,
www.clinicaltrials.gov, NCT#00916409).
As expected with a local treatment, toxicity was lim-
ited to skin irritation from transducer arrays (Fig. 1B).
After proper instructions, most patients became inde-
pendent in handling this device and replacing transducer
arrays, allowing them to be ambulatory and even going
to work. Despite the inconvenience of carrying andusing the device almost permanently, compliance was
high and patients reported improvement in QoL in the
absence of chemotherapy related toxicities.
In vitro and animal experiments suggest enhanced
eﬀect when TTF is combined with chemotherapy.28,32
We therefore initiated a subsequent randomised phase
III trial currently enrolling newly diagnosed glioblas-
toma patients after completion of standard radio-
chemotherpy, parallel to starting the adjuvant or
maintenance temozolomide chemotherapy. Patients
randomised to the experimental arm will receive TTF
in addition to maintenance temozolomide (www.
clinicaltrials.gov, NCT#00916409).
Based on the result of this trial TTF therapy has
recently been approved in the US and Europe for the
treatment of recurrent glioblastoma (www.fda.gov/News
Events/Newsroom/PressAnnouncements/ucm251669.
htm).
The universal anti-cancer eﬀect of TTF may be appli-
cable to other solid tumour types, alone or in combina-
tion with chemotherapy. In particular, in a situation of
morbidity induced by a heavy local tumour burden,
and in conditions where further radiotherapy is not an
option, this non-invasive treatment may allow for a clin-
ical beneﬁt and will substantially expand our treatment
armamentarium.
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